High doses of statins may reduce the lipid content in severe injury

Original title: Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy. The YELLOW Trial (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy). Reference: Annapoorna S. Kini et al. J Am Coll Cardiol 2013;62:21–9.

Multiple studies have shown the benefits of statins in reducing all events, stabilize plaques and improve endothelial function. Coronary intravascular ultrasound (IVUS) reduction in nonsignificant atherosclerotic plaque volume has been objectivized after administration of statins, however severe plaque effect is unknown.

The aim of this study was to determine the impact of intensive lipid lowering over the lipid content and the physiology of severe plaques using spectroscopy (NIRS = near-infrared spectroscopy), fractional flow reserve (FFR) and IVUS. 87 patients were randomized to standard versus intensive lipid-lowering therapy (Rosuvastatin 40 mg) which were treated in a programmed culprit injury but also having other stenosis lesions with a diameter of> 70% and measuring FFR ≤ 0.8. None of the non-culprit injuries received angioplasty at the time of randomization. After 6 to 8 weeks these non-culprit injuries were evaluated again using angiography, FFR, IVUS and NIRS before any angioplasty. At the end of follow-up, cholesterol values

More articles by this author

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...